April - June 2005, Volume 1, Issue 2
Editorial
This Article
Services
Google Scholar
PubMed
Acta Endocrinologica (Buc)
Catrina SB, Brismar K
Diabetic foot ulcers. Where we are and where are we going?
Acta Endo (Buc) 2005, 1 (2): 213-218doi: 10.4183/aeb.2005.213
Keywords:
Correspondence: Sergiu-Bogdan Catrina, MD, PhD, Department of Molecular Medicine, Karolinska Hospital, M1:02, Stockholm, S-17176, Sweden, tel: +46-(0)8-51774727;\r\n+46-(0)8-51775779, email: Sergiu-Bogdan.Catrina@molmed.ki.se
References:
1. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998; 176(2A Suppl):5S-10S.
2. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990; 13(5):513-521.
[CrossRef]
3. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the nagement of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24(2):290-295.
[CrossRef]
4. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19(4):350-354.
[CrossRef]
5. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003; 90(2):133-146.
[CrossRef]
6. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomize
[CrossRef]
7. Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol 1995; 132(1):79-85.
[CrossRef]
8. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7(6):442-452.
[CrossRef]
9. Catrina SB, Lewitt M, Massambu C, Dricu A, Grunler J, Axelson M et al. Insulin-like growth factor-I receptor activity is essential for Kaposi?s sarcoma growth and survival. Br J Cancer 2005; 92(8):1467- 1474.
[CrossRef]
10. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9(5):604-613.
[CrossRef]
11. Hehenberger K, Heilborn JD, Brismar K, Hansson A. Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of l-lactate. Wound Repair Regen
[CrossRef]
12. Loot MA, Kenter SB, Au FL, van Galen WJ, Middelkoop E, Bos JD et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002; 81(3):153-160.
[CrossRef]
13. Hehenberger K, Hansson A. High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors. Cell Biochem Funct 1997; 15(3):197-201.
[CrossRef]
14. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44(11):1973-1988.
[CrossRef]
15. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42(6):801-813.
[CrossRef]
16. Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999; 22(1):147-151.
[CrossRef]
17. Ballard JL, Eke CC, Bunt TJ, Killeen JD. A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. J Vasc Surg 1995; 22(4):485-490.
[CrossRef]
18. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications 2002; 16(2):153-158.
[CrossRef]
19. Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg 2005; 92(1):24-32.
[CrossRef]
20. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58(6):2351-2366.
[CrossRef]
21. O?Toole EA, Marinkovich MP, Peavey CL, Amieva MR, Furthmayr H, Mustoe TA et al. Hypoxia increases human keratinocyte motility on connective tissue. J Clin Invest 1997; 100(11):2881-2891.
[CrossRef]
22. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003; 162(1):303-312.
[CrossRef]
23. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxiainducible factor-1alpha protein stability and function. Diabetes 2004; 53(12):3226-3232.
[CrossRef]
24. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxiainducible factor-1alpha. Genes Dev 2001; 15(19):2520-2532.
[CrossRef]
25. Breitbart AS, Laser J, Parrett B, Porti D, Grant RT, Grande DA et al. Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg 2003; 51(4):409-414.
[CrossRef]
26. Crombleholme TM. Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen 2000; 8(6):460-472.
[CrossRef]
27. Lee PY, Chesnoy S, Huang L. Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol 2004; 123(4):791-798.
[CrossRef]
28. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000; 8(6):480-493.
[CrossRef]
29. Sivan-Loukianova E, Awad OA, Stepanovic V, Bickenbach J, Schatteman GC. CD34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds. J Vasc Res 2003; 40(4):368-377.
[CrossRef]